A phase IIIB, randomized trial of open-label efavirenz or atazanavir with ritonavir in combination with double-blind comparison of emtricitabine/tenofovir or abacavir/lamivudine in antiretroviral-naive subjects.

Trial Profile

A phase IIIB, randomized trial of open-label efavirenz or atazanavir with ritonavir in combination with double-blind comparison of emtricitabine/tenofovir or abacavir/lamivudine in antiretroviral-naive subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Atazanavir (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202), published in the Journal of Infectious Diseases.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Mar 2017 Results of a post-hoc analysis (n=269) assessing changes in BMD and phosphaturia after initiation of tenofovir disoproxil fumarate, published in the Journal of Antimicrobial Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top